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Abstract
Background/Aim. Granulocyte colony-stimulating
factor (G-CSF) reduces myocardial injury and
improves cardiac function after myocardial infarction
(MI). We investigated the early alterations provided
by G-CSF and the chronic repercussions in infarcted
rats. Methods. Male Wistar rats (200-250g) received
vehicle (MI) or G-CSF (MI-GCSF) (50 µg/kg, sc) at 7,
3 and 1 days before MI surgery. Afterwards MI was
produced and infarct size was measured 1 and 15
days after surgery. Expression of anti- and
proapoptotic proteins was evaluated immediately
before surgery. 24 hours after surgery, apoptotic
nuclei were evaluated. Two weeks after MI, left
ventricular (LV) function was evaluated, followed by
in situ LV diastolic pressure-volume evaluation.
Results. Infarct size was decreased by 1 day pre-
treatment before occlusion (36±2.8 vs. 44±2.1% in
MI; P<0.05) and remained reduced at 15 days after
infarction (28±2.2 vs. 36±1.4% in MI; P<0.05). G-CSF
pretreatment increased Bcl-2 and Bcl-xL protein
expression, but did not alter Bax in LV. Apoptotic nuclei
were reduced by treatment (Sham: 0.46±0.42, MI:
15.5±2.43, MI-GCSF: 5.34±3.34%; P<0.05). Fifteen
days after MI, cardiac function remained preserved
in G-CSF pretreated rats. The LV dilation was reduced
in MI-G-CSF group as compared to MI rats, being
closely associated with infarct size. Conclusion. The
early beneficial effects of G-CSF were essentials to
preserve cardiac function at a chronic stage of
myocardial infarction.
Introduction
Experimental myocardial infarction (MI) has been
widely used to study the development of heart failure.
Post-infarction cardiac remodeling leads to structural and
molecular changes throughout the myocardium, including
both ischemic and non-ischemic areas. One of the key
markers of cardiac failure after infarction is left ventricular
(LV) enlargement, which is mainly determined by the
infarct size but also by slippage of myocyte strands leading
to wall thinning and chamber dilation [1, 2]. Apoptosis is
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an important type of cell death, and it contributes to the
increase in infarct size during the acute phase of MI [3].
These early changes lead to severe hemodynamic
impairments such as increased LV filling pressure and
pump failure [4], representing a major cause of long-term
mortality in infarcted animals [5].
Granulocyte colony-stimulating factor (G-CSF) is a
20 kDa polypeptide with hematopoietic actions that is
produced by several cell lineages. Recently, its ability to
mobilize bone marrow-derived stem cells has led some
authors to test the potential effect of this cytokine in heart
failure therapy [6]. Orlic et al. [7] showed that pre-
treatment with G-CSF and stem cell factor (SCF) in mice
attenuated post-infarction cardiac remodeling and
improved myocardial function and survival, possibly by
cardiac regeneration. Others have also observed cardiac
tissue regeneration after MI with G-CSF therapy [8, 9].
This effect, however, was not found in other studies. Deten
et al. [10] showed that pre-treatment with G-CSF plus
SCF did not improve cardiac function after infarction and
did not observe any evidence of cardiac tissue
regeneration.
Some studies have shown that G-CSF alters the
course of LV remodeling. In a swine model of MI, G-
CSF treatment reduced infarct size and improved cardiac
function [11]. In addition, Sugano et al. [12] observed
that the acceleration of the healing process in the infarct
zone mediated by G-CSF treatment led to decreased
ventricular expansion in infarcted rats. It was also
demonstrated that long-term use of low-dose G-CSF
improved cardiac function [13]. It has not yet been
determined, however, if the effects of G-CSF in the acute
phase of myocardial infarction are effective in altering
post-infarction remodeling. Thus, our purpose in the
present study was to test the effects of G-CSF in the
acute infarct phase and its repercussions for the
development of heart failure.
Materials and Methods
Animals and experimental groups
Male Wistar rats (200-250 g) were randomly selected to
receive three doses of G-CSF (Biosintetica, 50 µg/kg,
subcutaneous) or vehicle (saline) at 7, 3 and 1 days before
surgical procedures. Pre-treated animals (control and G-CSF)
were subjected to coronary artery ligature to produce MI
twenty-four hours after the final G-CSF treatment. Sham
surgeries (SO) were performed in a sample of animals to be
used as non-infarcted controls. A subset of animals from each
group was killed before any surgical manipulation to determine
the effects of G-CSF treatment in the apoptosis-related proteins
in the heart. During the pre-treatment period and after surgery,
all animals were maintained in a 12-hour light-dark cycle and
had free access to water and rodent chow. The experiments
were carried out in accordance with the Guide for the Care and
Use of Laboratory Animals (NIH Publication No. 85-23, revised
1996) and approved by the institutional animal research
committee.
White blood cell counting
Blood samples (20 µL) were collected by puncture of the
safena vein before the first dose and immediately before the
surgical procedure to produce MI or SO and were homogenized
in a lysis solution containing 2% acetic acid (380 µL). White
blood cells (WBC) were quantified in a Neubauer chamber.
Western blot
A sample of animals (six male pre-treated with G-CSF and
six pre-treated with vehicle) was killed twenty-four hours after
the last dose of G-CSF. The animals were killed by decapitation,
and the heart was rapidly removed and rinsed in cold saline
solution. The LV was separated and minced. A sample from the
LV was weighed and homogenized in buffer (100 mM Tris (pH
7.4), 1 % SDS, 10 mM Na3VO4, 100 mM NaF, 100 mM Na4P2O7,
and 10 mM EDTA) and then centrifuged at 12000 g for 30 min at
4º C to remove the insoluble material. Protein concentration
was determined by the Lowry method. Equal amounts of protein
(75 μg) from each sample were treated with Laemmli buffer
(BioRad Laboratories), resolved by 12% polyacrylamine gel
electrophoresis (SDS-PAGE) and transferred to a nitrocellulose
membrane (Amersham Biosciences) by electroblotting. The
membrane was blocked with Tris-buffered solution (10 mM
Tris, 100 mM NaCl and 0.1% Tween 20) containing 5% of non-
fat milk for 2 hours and then incubated overnight at 4º C with
the appropriate primary antibody diluted in the block solution.
The specific primary antibodies used were anti-Bcl-2 (dilution
1:750; Santa Cruz Biotechnology Inc., CA, USA), anti-Bax
(dilution 1:750; Santa Cruz Biotechnology Inc., CA, USA), and
anti-Bcl-xL (dilution 1:750; Santa Cruz Biotechnology Inc., CA,
USA). The membranes were then incubated with the respective
peroxidase-conjugated secondary antibody (Amersham
Biosciences) for 1 hour. Visualization of specific protein bands
was performed using the enhanced chemiluminescence reagent
ECL Plus (Amersham Biosciences) with exposure to
photographic film. Densitometry was performed using a
computerized digital image system (Scion Image, National
Institute of Health). Within the same membrane, α-tubulin
protein expression was also determined (anti-α-tubulin, dilution
1:500; Zymed Laboratories, CA, USA), and its content was
used as an internal control.
Surgical procedures and infarct size measurement
Myocardial infarctions were performed by an investigator
blinded to the treatment groups, as previously described [14].
Briefly, under pentobarbital anesthesia (50 mg/kg, i.p.), a
thoracotomy was performed at the level of the fourth intercostal
space to expose the heart. The left coronary artery was
permanently occluded with a 6.0 suture, and the heart was
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immediately returned to the thorax. Sham-operated (SO) rats
were subjected to all procedures except the coronary occlusion.
To determine the acute cardiac changes produced by G-
CSF pre-treatment, a sample of animals was sacrificed twenty-
four hours after surgery to evaluate infarct size. The left ventricle
was incubated with 1% triphenyltetrazolium chloride (TTC) in
a buffer solution at 37º C for 10 minutes. Under microscope
visualization, the ischemic area was separated from non-
ischemic tissue and measured by planimetry (ImageJ v. 1.43;
National Institute of Health, USA). Another group of animals
was studied two weeks after the surgery. The infarct scar was
carefully separated from viable tissue under a microscope and
weighed, and the areas occupied by the scar tissue and by the
remaining LV muscle were measured by planimetry. Infarct size
was reported as the percentage of the scar area within the total
LV area [14].
TUNEL assay
Twenty-four hours after SO or coronary ligation surgery,
a random sample (5 animals per group) was used for the
evaluation of apoptosis in the left ventricular myocardium. The
hearts were excised, perfused with formalin solution and
embedded in paraffin. After embedding, 4 µm sections were
cut.
A terminal deoxynucleotidyl transferase-mediated dUTP
nick end-labeling (TUNEL) assay was used to identify double-
stranded DNA fragmentation. Each section was deparaffinized
and rehydrated with graded xylenes and ethanols. Proteinase
K was applied for 30 min to induce proteolysis. The endogenous
peroxidase was inhibited with 3% hydrogen peroxide for 10
min. Detection of apoptosis was performed using a commercial
kit (Roche Diagnostics, Indianapolis, IN, USA). The TdT
reaction was carried out for 1 hour at 37° C, and then 3,3’-
diaminobenzidine tetrahydrochloride chromogen was applied.
Harris hematoxylin was used as a counterstain. Images were
acquired using an optical microscope (DM2500, Leica, Wetzlar,
Switzerland). TUNEL-positive cells were determined in the
ischemic area by randomly counting 5 fields per section, and
the data were expressed as a percentage of apoptotic nuclei to
total nuclei.
LV function measurement and pressure-volume
evaluation
Two weeks after the surgery, the animals were
anesthetized with ketamine (Agener União, Brazil) and xylazine
(Bayer, Brazil) (70/10 mg/kg, i.p.) to evaluate LV function. The
right common carotid artery was separated from the surrounding
connective tissue and catheterized. A heparinized polyethylene
catheter (P50) connected to a pressure transducer (TRI 21,
Letica Scientific Instruments, Spain) and a digital system
(Powerlab/4SP ML750, ADInstrument, Australia) was then
inserted into the LV and the readings was saved for later analysis.
Heart rate (HR), left ventricular systolic (LVSP), end-diastolic
pressure (LVEDP), and the maximum rate of pressure rise (+dP/
dt) and fall (-dP/dt) were assessed.
After hemodynamic measurements, the heart was arrested
with 3 M KCl, and a double-lumen catheter (P50 inserted into
P200) was inserted into the LV through the aorta to determine
the in situ LV diastolic pressure-volume relationship to measure
the dilation of the chamber [15]. The atrio-ventricular groove
was occluded, and a small incision was made in the right
ventricular free wall to avoid any compressor effect. Then, 0.9%
NaCl solution was infused with an infusion pump (BI 200, Insight
Equipamentos, Brazil) at 0.68 mL/min into P200 catheter, and
intraventricular pressure was continuously monitored with the
P50 catheter. Fluid was infused until the pressure reached 30
mmHg. Three curves were recorded for each heart for
approximately ten minutes. LV dilation was obtained through
the slope of pressure-volume curve [15].
Statistical analysis
All data are presented as the mean ± standard error of
mean (SEM), and significance was set at P<0.05. Comparisons
between two means were made using the Student’s t-test, and
more than two groups were compared using one-way analysis
of variance (ANOVA), followed by a Bonferroni correction.
When data did not follow a Gaussian distribution, a Kruskal-
Wallis test was used. A Pearson correlation was performed to
test the association between dilation index and the infarct size.
Linear regression analysis was used to obtain the linear slope




All groups showed similar white blood cell counts
before the onset of treatment (12,820 ± 580 cells/mm3 in
SO animals, 12,300 ± 365 cells/mm3 in the MI group and
12,258 ± 398 cells/mm3 in the MI-GCSF group, P>0.05).
Immediately before the surgical procedure, there was no
difference between SO (13,272 ± 413 cells/mm3) and
MI (12,535 ± 320 cells/mm3) rats. However, a significant
increase in white blood cells was observed in the G-CSF
pre-treated group (22,673 ± 849 cells/mm3) was
designated to undergo the coronary occlusion.
Proteins expression and apoptotic nuclei
detection
To evaluate the effect of G-CSF on the intrinsic
apoptotic pathway, protein expression was evaluated
twenty-four hours after the final dose of G-CSF or saline
in pre-treated rats (the animals were killed at the time
that they would have undergone the surgery). As observed
in Fig. 1, Bcl-2 (0.88 ± 0.09 in G-CSF vs. 0.52 ± 0.06 in
control, P<0.05) and Bcl-xL (0.56 ± 0.08 in G-CSF vs.
0.3 ± 0.02 in control, P<0.05) protein expression increased
significantly in the LV of rats subjected to G-CSF pre-
treatment, suggesting that G-CSF treatment enhances
protection from apoptosis in the myocardium. However,
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protein expression of Bax remained unchanged with G-
CSF pre-treatment (0.59 ± 0.1 in G-CSF vs. 0.55 ± 0.12
in control, P>0.05) (Fig. 1).
Twenty-four hours after myocardial infarction,
apoptotic nuclei were evaluated using a TUNEL assay.
Fig. 2 shows an increase in TUNEL-positive nuclei after
MI, which was reduced by G-CSF pre-treatment (SO:
0.46 ± 0.42, MI: 15.5 ± 2.43, MI-GCSF: 5.34 ± 3.34%;
P<0.05).
Myocardial infarction and chamber weight
Twenty-four hours after coronary occlusion, TTC
staining showed that pre-treatment with G-CSF reduced
infarct area compared to the non-treated rats (36 ± 2.8%
vs. 44 ± 2.1% in the MI group; P<0.05) (Fig. 3). Similarly,
two weeks after coronary occlusion, the infarct size was
also significantly reduced in MI-G-CSF rats compared to
MI rats (27.2 ± 2.2% vs. 35.9 ± 1.4% in the MI group,
P<0.05) (Fig. 4B). However, the scar weight was similar
in both groups (0.33 ± 0.03 in MI and 0.27 ± 0.03 g in
MI-G-CSF), suggesting that the scar thickness in G-CSF
pre-treated animals was greater than in the untreated
infarcted group. Right ventricle hypertrophy was not
observed in MI group, despite a trend (P=0.07).
Hemodynamic parameters and LV pressure-
volume relationship
Table 1 shows the results of hemodynamic
measurements 15 days after SO or coronary ligature.
The cardiac catheterization showed an increase in
Fig. 2. TUNEL-positive nuclei evaluated in the LV twenty four
hours after MI or fictitious surgery. Head arrow shows apoptotic
nuclei. Data were compared using Kruskal-Wallis test and are
depicted as mean ± SEM. * P < 0.05 vs. SO; # P < 0.05 vs. MI.
Fig. 3. Infarct size measured 24 hours after coronary occlusion,
by TTC method, depicted as percentage of infarcted area to
total LV area. MI (n=17) and MI-GCSF (n=18). Data were
compared using Student t test and are depicted as mean ±
SEM. * P < 0.05 vs. MI.
Fig. 1. Left ventricle protein
expression of Bcl-2 (26 kDa), Bcl-xL (30
kDa) and Bax (23 kDa) by Western blot,
immediately before myocardial
infarction. Control (n=6) and GCSF
(n=6). Data are mean ± SEM. * P < 0.05.
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LVEDP and a decrease in peak LVSP and dP/dt after
infarction. Animals infarcted after pre-treatment with G-
CSF had a preserved LVSP (Table 1) and a reduced
increase in LVEDP. Both LV contractility (+dP/dt) and
relaxation (-dP/dt) were less affected in rats pre-treated
with G-CSF.
Fig. 4 (panel A) shows the LV pressure-volume
curves obtained in arrested hearts in all groups. As
expected, myocardial infarction induced a rightward shift,
indicating more intra-ventricular volume at the same
distending pressure. However, G-CSF pre-treatment
abolished this effect (SO: 42.8 ± 3.5; MI: 19.9 ± 2.5; MI-
G-CSF: 41 ± 5 mmHg/mL; P<0.05), indicating that G-
CSF reduces LV dilation caused by myocardial infarction.
A strong negative correlation (r = -0.83, P<0.05; Fig. 4C)
was observed between the LV dilation index and infarct
size, suggesting an effect of infarct size on the LV dilation
process.
To further evaluate the effect of changes in infarct
size on the reduced left ventricular dilation found in G-
CSF treated animals, we conducted a subgroup analysis
(seven animals per group) by comparing the pressure-
volume curves of MI and MI-G-CSF rats with paired
infarct areas. LV pressure-volume relation was similar
in both infarcted groups (MI = 21.2 ± 2; MI-G-CSF =
25.1 ± 4.2; P>0.05, Fig. 5), suggesting that the reduction
in LV dilation produced by G-CSF pre-treatment is related
to the early reduction in infarct size.
Discussion
Our results show that pre-treatment with G-CSF
preserves left ventricular function through early infarct
size reduction and the attenuation of cardiac remodeling
after MI, even after the treatment was stopped. These
Fig. 4. (A) LV pressure-volume curve at
0 to 30 mmHg. (B) Infarct area evaluated
two weeks after coronary occlusion. (C)
Correlation between infarct area and
dilation index. Data are mean ± SEM. * P
< 0.05 vs. SO; # P < 0.05 vs. MI-GCSF.
Table 1. Hemodynamic and morphometric parameters at
two weeks after myocardial infarction HR, heart rate; LVSP,
left ventricular systolic pressure; LVEDP, left ventricular end
diastolic pressure, dP/dt, maximum rate of pressure rise
and fall; BW, body weight; LV, left ventricle; RV, right ventricle.
Data are presented as mean ± SEM. * P<0.05 vs. SO # P<0.05
vs. MI.
Fig. 5. LV pressure-volume curve performed in a sample of
infarcted animals with same infarct area. * P < 0.05 vs. SO.
results suggest that the long-term benefits found in G-
CSF pre-treated rats are associated with anti-apoptotic
protein upregulation and an early reduction in
cardiomyocyte apoptosis. Moreover, our results strongly
suggest that the reduced chamber dilation found in the
G-CSF Reduces Apoptosis After Infarction in Rats Cell Physiol Biochem 2011;28:33-40
38
G-CSF pre-treated rats was dependent on the reduction
in infarct size.
Mobilized bone marrow-derived stem cells can
migrate to the ischemic heart to presumably help
regenerate the infarcted myocardium, as previously
reported [7, 16]. The homing of bone marrow-derived
cells is mediated by stromal-derived factor (SDF-1)
interaction with the receptor CXCR-4. These CXCR-4+
cells help mediate angiogenesis and cell survival in the
myocardium [17]. SDF-1 is upregulated soon after
myocardial infarction. As reported by Misao et al. [18],
specific inhibition of the CXCR-4 receptor blunted the
effect of G-CSF in infarcted rabbits. Moreover, it was
reported that this pathway is also impaired by the action
of the dipeptidylpeptidase IV, reducing cell homing and
compromising the beneficial effects of G-CSF in the
infarcted heart [19]. However, further studies have shown
that the contribution of this regenerative process, if
existent, is too modest to explain the improvement in
cardiac function related to this cytokine [20]. More recent
studies have demonstrated that post-infarction treatment
with G-CSF improves LV function and survival, showing
that this therapy may influence cardiac remodeling after
myocardial infarction [12, 21, 22]. All of these studies
assessed only the chronic effects of G-CSF, while its acute
effects were not addressed.
Our results, in agreement with other studies, suggest
a direct cytoprotective effect of G-CSF in the ischemic
heart. For instance, the addition of G-CSF to an isolated
perfused rat heart subjected to an ischemic injury led to
an early reduction in the ischemic lesion and an
improvement in LV function, showing a direct and likely
non-genomic effect of G-CSF on the ischemic
myocardium [23]. Harada et al. [24] failed to demonstrate
a reduction in infarct size three days after occlusion;
however, the authors showed a significant long-term
improvement in cardiac function in G-CSF-treated mice.
Here, we show that G-CSF pre-treated animals have
increased expression of myocardial anti-apoptotic proteins
such as Bcl-2 and Bcl-xL. Therefore, G-CSF-treated
animals, being protected from early ischemic insult, were
subjected to coronary ligature. Pre-treatment with G-CSF
reduced infarct size twenty-four hours after coronary
occlusion. This reduction was associated with a significant
reduction in cardiomyocyte apoptosis in the ischemic area.
Similarly, Harada et al. [24] observed increased levels of
Bcl-2 and Bcl-xL in the myocardium twenty-four hours
after infarction, but they did not observe a reduction in
infarct size until seven days later. Another study showed
that G-CSF-mobilized cells have enhanced expression of
cytoprotective genes that promote myocyte preservation
and cardiac repair [25]. Apoptosis is an important kind of
cell death in the early phase of myocardial infarction,
contributing to the limitation of infarct size [3, 26, 27].
The increased levels of antiapoptotic factors observed in
our study and the reduction in apoptosis soon after
myocardial infarction may explain the reduced infarct size
observed twenty-four hours after coronary ligature, which
was maintained for two weeks following surgery.
In our study, even though pre-treatment with G-CSF
was restricted to the period before coronary occlusion,
infarct size also decreased in treated animals two weeks
after infarction, which relates to the observed reduction
in ischemic injury twenty-four hours after surgery.
Therefore, this early reduction in infarct size may lead to
fewer remodeling effects, preventing infarct expansion
and directly impacting ventricular function. As reported,
G-CSF improves left ventricular function in infarcted rats
[12, 21, 24]. We found a similar effect two weeks after
myocardial infarction, even without treatment following
the surgery. This result suggests that the early effects of
G-CSF pre-treatment account for this hemodynamic
preservation. Accordingly, a significant infiltration of
inflammatory cells into the ischemic tissue was detected
two days after infarction in G-CSF treated rabbits,
contributing to infarct repair and improvements in cardiac
function [8]. Moreover, G-CSF expedites infarct repair
through increased collagen deposition in the ischemic
border zone, decreasing the left ventricular expansion
[12]. Because our treatment was administered prior to
myocardial infarction, the effects of this cytokine on the
remodeling process are restricted to infarct size limitation
through decreased apoptosis. Thus, improvement in
cardiac function is related to changes in infarct size.
Pressure-volume curves showed that myocardial
infarction contributed to left ventricular dilation as seen
by the rightward shift of the pressure volume curve.
Myocardial infarction leads to progressive left ventricular
expansion, contributing to systolic dysfunction and heart
failure [4]. We observed that pretreatment with G-CSF
inhibits ventricular expansion and that pre-treated rats
have a significant reduction in LV volume. Deindl et al.
[28] showed that G-CSF treatment improved cardiac
function and shifted the LV pressure volume-curve to
the left. Moreover, chamber dilation correlates with infarct
size, impacting ventricular function and survival [5, 29].
It is widely known that large infarct size is associated
with a poor prognosis. Here, we observed a strong
negative correlation between left ventricular dilation and
infarct size, suggesting that the effects of G-CSF during
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the early phase of myocardial infarction are essential in
maintaining LV structure and function. To corroborate
this conclusion, we analyzed a sample with similar infarct
areas, and any differences were noted, underlining the
crucial role of infarct size in determining post-infarction
outcomes.
Taken together, our data indicate that the
reduction in infarct size caused by the antiapoptotic
effect of pretreatment with G-CSF is essential for its
effects on post-infarction left ventricular remodeling. We
cannot exclude the possibility that the observed effects
of treatment with G-CSF are not just restricted to the
acute phase. It has been previously reported that
treatment with this cytokine in animals with chronic heart
failure was sufficient to improve left ventricular function
[30, 31]. Here, we show the important contribution of the
acute effects of G-CSF in limiting heart failure
progression. Therefore, the acute effects of G-CSF
closely following infarction may help preserve long-term
cardiac function [32].
A clear limitation of our study is that G-CSF was
administered before myocardial infarction, which is
uncommon in clinical cases. However, our study clearly
shows that after G-CSF pre-treatment, apoptosis is
prevented in the early stages of myocardial injury, infarct
size is reduced by up to 20% and LV dilation is limited,
thus preserving LV systolic and diastolic function.
However, the kinetics and dose response of G-CSF must
be determined in further studies to attain optimal benefits.
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